XLONRENE
Market cap2mUSD
Feb 05, Last price
3.38GBP
Name
ReNeuron Group PLC
Chart & Performance
Profile
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized packages of information released by CTX cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | 2016‑03 | 2015‑03 | |
Income | |||||||||
Revenues | 530 31.51% | 403 56.81% | |||||||
Cost of revenue | 10,057 | 17,263 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (9,527) | (16,860) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (1,249) | (1,369) | |||||||
Tax Rate | |||||||||
NOPAT | (8,278) | (15,491) | |||||||
Net income | (5,408) -44.18% | (9,689) -14.61% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 1,000 | 23 | |||||||
BB yield | |||||||||
Debt | |||||||||
Debt current | 153 | 146 | |||||||
Long-term debt | 689 | 978 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (6,311) | (13,424) | |||||||
Cash flow | |||||||||
Cash from operating activities | (7,484) | (7,411) | |||||||
CAPEX | (220) | (302) | |||||||
Cash from investing activities | 4,911 | (276) | |||||||
Cash from financing activities | (147) | 2,366 | |||||||
FCF | (8,238) | (15,466) | |||||||
Balance | |||||||||
Cash | 7,153 | 14,548 | |||||||
Long term investments | |||||||||
Excess cash | 7,126 | 14,528 | |||||||
Stockholders' equity | (111,091) | (106,260) | |||||||
Invested Capital | 116,473 | 116,607 | |||||||
ROIC | |||||||||
ROCE | |||||||||
EV | |||||||||
Common stock shares outstanding | 57,126 | 56,976 | |||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | (9,260) | (16,536) | |||||||
EV/EBITDA | |||||||||
Interest | 20 | 25 | |||||||
Interest/NOPBT |